中心性浆液性脉络膜视网膜病变患者应用高压氧联合卵磷脂络合碘治疗的研究

Study on the application of hyperbaric oxygen combined with iodized lecithin in the treatment of central serous chorioretinopathy

目的分析中心性浆液性脉络膜视网膜病变（CSC）患者应用高压氧联合卵磷脂络合碘治疗的临床疗效及安全性。方法随机选取2012年12月~2013年12月本院诊治的98例（108眼）中心性浆液性脉络膜视网膜病变患者,按照随机双盲法分为两组,对照组49例予以高压氧治疗,研究组49例在对照组基础上联合卵磷脂络合碘治疗,分析两组患者视力恢复及不良反应情况。结果两组患者治疗后视力均明显恢复,且研究组患者的视力明显优于对照组,比较差异均具有统计学意义（P〈0.05）,研究组治疗后复发情况明显少于对照组,比较差异具有统计学意义（P〈0.05）;同时,两组患者的不良反应情况比较差异不明显,且均经临床对症治疗后缓解。结论应用高压氧联合卵磷脂络合碘治疗中心性浆液性脉络膜视网膜病变的临床疗效显著,且用药过程安全可靠。

Objective To analyze the clinical efficacy and safety of hyperbaric oxygen combined with iodized lecithin in the treatment of central serous chorioretinopathy （CSC）. Methods 98 cases （ 108 eyes） of patients with central serous chorioretinopathy in our hospital from December 2012 to December 2013 were randomly selected, which according to the randomized double blind method were divided into two groups, each with 49 eases. While the 49 cases of patients in the control group were given hyperbaric oxygen therapy, the 49 cases in the study group were treated with hyperbaric oxygen combined with iodized lecithin. The recovery of visual acuity and adverse reaction of the two groups were analyzed. Results After the treatment, visual acuity of patients in both the two groups were significantly restored, and that of the study group was significantly better than the control group, with statistically significant difference （P 〈 0.05 ）. Recurrence in the study group was significantly less than the control group after the treatment, with significant difference （P 〈 0.05 ）. Moreover, the adverse reactions in two groups of patients showed no significant difference, and both were alleviated after clinical symptomatic treatment was given. Conclusion Hyperbaric oxygen combined with iodized lecithin is with significant curative effect in the treatment of central serous chorioretinopathy, and its medication is safe and reliable.